Clinical trial
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children Aged 6~35 Months
NCT03020628 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children Aged 6~35 Months
- Lead sponsor
- SK Chemicals Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- June 30, 2017
- Enrollment
- 171 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.